Niedel James

Avg. Two Year Performance

No purchase track record
38% Avg. Sale Return
17% Compound
1 Mo3 Mo6 Mo1 Yr2 Yr
Average Purchase Return184%166%124%250%0%
Purchase Success Rate1 of 11 of 11 of 11 of 10 of 1
Average Sale Return(5%)(27%)(37%)(77%)38%
Sale Success Rate0 of 20 of 20 of 20 of 21 of 2

Chimerix, Inc.

Drugs » Biotechnology

Director:

Holdings: 1.05M shares

Sentiment

Insider Trading Sentiment: Hold

Avg. Two Year Performance

No purchase track record
No sale track record

Last Three Months:

0 Net Amount
Buy:0--
Sell:0--